Servi­er says its next IDH in­hibitor has passed PhI­II, but no reg­u­la­to­ry time­line yet

Servi­er’s IDH in­hibitor vo­rasi­denib has passed its Phase III tri­al in low-grade glioma, the com­pa­ny an­nounced Tues­day morn­ing. How­ev­er, it left its reg­u­la­to­ry time­line up in the air.

The drug met the pri­ma­ry end­point of pro­gres­sion-free sur­vival as well as a sec­ondary end­point of time to next in­ter­ven­tion, Servi­er said. But when asked for more de­tails in an in­ter­view with End­points News, Servi­er’s VP of clin­i­cal de­vel­op­ment Su­san Pandya de­clined to com­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER